Genentech, Inc.

Boehringer Ingelheim International Gmbh

F. Hoffmann-La Roche Ag

Elisia Villemure

Matthew Volgraf

Huifen Chen

Robin Larouche-Gauthier

Aijun Lu

Lea Constantineau-Forget

Yu Jiang

Claudio F Sturino

Guosheng Wu

Daniel Shore

Vishva M Dixit

Pierre Louis Beaulieu

Jacob Bradley Schwarz

Po-Wai Yuen

Benoît Moreau

Stuart Ward

Cuong Q Ly

Joachim Rudolph

Anthony A Estrada

Brian Salvatore Safina

Jean Rancourt

Steven Huy Do

Lewis J Gazzard

Steven T Staben

Aleksandr Kolesnikov

Murray D Bailey

Michael Siu

Cédrickx Godbout

Andrew Peter Cridland

Vishal Verma

Lan Wang

Francis Beaumier

Luce Lépissier

Jack Alexander Terrett

Benjamin Douglas Sellers

Samantha Alyson Green

Chantal Grand-Maître

Martin Déry

Chantal Grand-Maitre

Baihua Hu

Oliver Hucke

Martin Dery

Jessica Grandner

Mingshuo Zeng

Lee Fader

Martin Poirier

Carl Thibeault

Binqing Wei

Simon Surprenant

Melissa Leblanc

Francois Bilodeau

Rebekah J Carson

Eric Jolicoeur

Julie Naud

Jiang Yu

Cyrille Kuhn

Jean-Eric Lacoste

Xingyu Lin

Neri Amara

André Giroux

Olivier Lepage

Benjamin Sellers

Anne Décor

Mélissa Leblanc

Marc-André Joly

Matthew Leo Landry

Christian Nilewski

Steven Thomas Staben

Andrew Cridland

Chantal Grand-MAÎTRE

Martin DÉRY

Luce LÉPISSIER

Claudio Sturino

The invention provides a compound of formula (I): or a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein Rand Rhave any of the values described in the specification, as well as compositions comprising a compound of formula (I) or a prodrug thereof, or a pharmaceutically acceptable salt thereof. The compounds are agonists of glycolytic enzyme phosphofructokinase-1 liver type and are useful for treating diseases associated with the activity of glycolytic enzyme phosphofructokinase-1 liver type, such as cancer, diabetes, sepsis, and septic shock.

Therapeutic compounds and methods

The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.

Therapeutic compounds

Provided herein are aza-tetracyclic oxazepinyl compounds useful in the treatment of cancers.

Aza-tetracyclic oxazepine compounds and uses thereof

The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R, Rand n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Oxadiazole transient receptor potential channel inhibitors

The invention relates to methods of using compounds formula I: and pharmaceutically acceptable salts thereof wherein A, X, R, Rand n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

The invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as respiratory disorders or pain.

Oxadiazolones as transient receptor potential channel inhibitors

The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

Thiazolopyrimidinones and methods of use thereof

The invention relates to pyridopyrimidinone compounds of formula I or pharmaceutically acceptable salts thereof, wherein X, R, R, R, R, Rand Rare as defined herein, as well as pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

Pyridopyrimidinones and methods of use thereof

The invention is concerned with the compounds of formula I: and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.

Substituted sulfonamide compounds

Compounds of Formula (I) wherein R, R, R, R, Y, Zand Zare defined herein, are useful for the treatment of cytomegalovirus disease and/or infection. 

Inhibitors of cytomegalovirus

Growing community of inventors

San Francisco, CA, United States of America

Elisia Villemure